<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715232</url>
  </required_header>
  <id_info>
    <org_study_id>1.1-20150511</org_study_id>
    <nct_id>NCT02715232</nct_id>
  </id_info>
  <brief_title>Effects of Sex Steroids on the Serotonin System</brief_title>
  <official_title>Effects of Sex Steroid Hormones on Serotonin Synthesis and Degradation Measured With PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to prove the modulatory influence of sex hormones on serotonergic
      neurotransmission by determining the enzymatic processes involved in serotonin synthesis and
      degradation using positron emission tomography (PET) in humans in vivo with the radiotracers
      [11C]AMT and [11C]harmine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Sex hormones such as estradiol and testosterone modulate human brain structure and function
      and are tightly connected to neuropsychiatric disorders such as depression and anxiety
      disorders. Using molecular imaging in humans in vivo, the investigators showed strong
      influences of sex hormones on serotonergic neurotransmission via modulation of serotonergic
      receptors and transporters. Although, animal studies also indicate strong modulatory
      influences on serotonin synthesis and degradation, human data on this potential effect are
      absent.

      Objectives of the study:

      The aim of this study is to prove the modulatory influence of sex hormones on serotonergic
      neurotransmission by determining the enzymatic processes involved in serotonin synthesis and
      degradation using positron emission tomography (PET) in humans in vivo with the radiotracers
      [11C]AMT and [11C]harmine.

      Study design:

      Single-blind, longitudinal study. Transsexuals will undergo four PET and two magnetic
      resonance imaging (MRI) measurements: 1. One [11C]AMT PET, one [11C]harmine PET and one MRI
      measurement before start of treatment, 2. One [11C]AMT PET, one [11C]harmine PET and one MRI
      measurement after 4 months of treatment. The investigators propose an overall study duration
      of 36 months.

      Materials and Methods:

      PET measurements will be performed on a GE Advance PET scanner. To examine the
      interdependence between serotonin activity and brain structure and function, four MRI
      sequences will be performed in order to assess gray matter volume and cortical thickness,
      gray and white matter microstructure, as well as resting state functional connectivity and
      cerebral blood flow. MRI measurements will be done on a 3 Tesla scanner with high spatial and
      temporal resolution.

      Study population:

      20 healthy female-to-male (FtM), 20 healthy male-to-female (MtF) transsexuals (aged 18-50)
      who are free of hormone-medication at baseline; 40 healthy controls, matched for sex, age and
      education level.

      Pilot Study:

      A pilot study without pharmacologic intervention consisting of one optional [11C]AMT PET and
      two [11C]harmine PET will be performed in 12 healthy controls in order to optimise PET
      measurement procedures.

      Relevance and implications of the study:

      This will be the first imaging study to investigate the effects of high-dose, long-term
      opposite-sex steroid hormones on serotonin synthesis and degradation in the living human
      brain using PET. The study will lead to the establishment of a comprehensive theory of
      serotonergic modulation by sex steroids and will increase knowledge on the serotonergic role
      in shaping brain morphology, microstructure and structural/functional connectivity. Results
      will provide essential data for a better understanding of neural sex differences associated
      with differences in hormonal states in humans and will elucidate neurobiological correlates
      of the known gender difference in the prevalence of neuropsychiatric disorders, thus
      contributing to the development of personalized treatment, the reduction of personal
      suffering and the reduction of costs and occupational disability.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood-to-brain clearance/trapping (K*) of [11C]AMT</measure>
    <time_frame>&lt;5 months</time_frame>
    <description>[11C]AMT trapping as an estimation of brain serotonin synthesis in vivo in humans</description>
  </primary_outcome>
  <primary_outcome>
    <measure>distribution volume (DV) of [11C]harmine</measure>
    <time_frame>&lt;5 months</time_frame>
    <description>distribution volume of specifically bound radioligand [11C]harmine in brain regions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>white and gray matter microstructure</measure>
    <time_frame>&lt;5 months</time_frame>
    <description>microstructure measured using diffusion weighted imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gray matter volume/density and cortical thickness</measure>
    <time_frame>&lt;5 months</time_frame>
    <description>structural MRI measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral blood flow (CBF)</measure>
    <time_frame>&lt;5 months</time_frame>
    <description>cerebral blood flow measured using arterial spin labeling MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores on the Klein Sexual Orientation Grid (KSOG)</measure>
    <time_frame>&lt;5 months</time_frame>
    <description>the KSOG measures sexual orientation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores on the Utrecht Gender Dysphoria Scale</measure>
    <time_frame>&lt;5 months</time_frame>
    <description>Score for gender dysphoria</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Gender Dysphoria</condition>
  <arm_group>
    <arm_group_label>Female-to-Males</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female-to-Male Transsexuals receiving Testosterone treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male-to-Females</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male-to-Female Transsexuals receiving Estradiol and Anti-androgen treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Female Controls receiving no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Male controls receiving no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme</description>
    <arm_group_label>Female-to-Males</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lynestrenol</intervention_name>
    <description>2-3 tablets/day, if menstruation still occurs</description>
    <arm_group_label>Female-to-Males</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyproterone Acetate</intervention_name>
    <description>25mg daily</description>
    <arm_group_label>Male-to-Females</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg</description>
    <arm_group_label>Male-to-Females</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin acetate</intervention_name>
    <description>4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.</description>
    <arm_group_label>Female-to-Males</arm_group_label>
    <arm_group_label>Male-to-Females</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-5 diagnosis of Gender Dysphoria (DSM-5: 302.85; ICD-10: F64.1) (for transsexuals
             only)

          -  Somatic health based on history, physical examination, ECG, laboratory screening, SCID

          -  willingness and competence to sign the informed consent form

        Exclusion Criteria:

          -  concomitant major medical or neurological illness

          -  internal or neurologic medical histories as well as pregnancy (positive urine
             pregnancy test) or breastfeeding

          -  other DSM-5 Axis-I comorbidities, determined by a structured clinical interview
             (SCID), especially body dysphoric disorder (DSM-5: 300.7; ICD-10: F45.22),
             schizophrenia spectrum and other psychotic disorders

          -  steroid hormone treatment within 6 months prior to inclusion

          -  treatment with psychotropic agents such as SSRIs

          -  any implant or stainless steel graft

          -  abnormal values in routine laboratory screening or general physical examination

          -  current substance abuse or current or past substance related disorder

          -  for participants who participated in an earlier neuroimaging study using ionizing
             radiation, the total radiation exposure dose of 20 mSv over the last 10 years must not
             be exceeded, as specified in the legislation on radiation protection (Allg.
             Strahlenschutzverordnung 2010; www.ris.bka.gv.at)

          -  failure to comply with the study protocol or to follow the instructions of the
             investigating team
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupert Lanzenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry and Psychotherapy, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rupert Lanzenberger, MD</last_name>
    <phone>+43 40400</phone>
    <phone_ext>35760</phone_ext>
    <email>rupert.lanzenberger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georg S Kranz, PhD</last_name>
    <phone>+43 40400</phone>
    <phone_ext>38250</phone_ext>
    <email>georg.kranz@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupert Lanzenberger, A/Prof.</last_name>
      <phone>+43 40400</phone>
      <phone_ext>3825</phone_ext>
      <email>rupert.lanzenberger@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Rupert Lanzenberger, A/Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biol Psychiatry. 2015 Oct 15;78(8):525-33. doi: 10.1016/j.biopsych.2014.09.010. Epub 2014 Sep 23.</citation>
    <PMID>25497691</PMID>
  </reference>
  <reference>
    <citation>Kranz GS, Hahn A, Kaufmann U, Küblböck M, Hummer A, Ganger S, Seiger R, Winkler D, Swaab DF, Windischberger C, Kasper S, Lanzenberger R. White matter microstructure in transsexuals and controls investigated by diffusion tensor imaging. J Neurosci. 2014 Nov 12;34(46):15466-75. doi: 10.1523/JNEUROSCI.2488-14.2014.</citation>
    <PMID>25392513</PMID>
  </reference>
  <reference>
    <citation>Hahn A, Kranz GS, Küblböck M, Kaufmann U, Ganger S, Hummer A, Seiger R, Spies M, Winkler D, Kasper S, Windischberger C, Swaab DF, Lanzenberger R. Structural Connectivity Networks of Transgender People. Cereb Cortex. 2015 Oct;25(10):3527-34. doi: 10.1093/cercor/bhu194. Epub 2014 Sep 12.</citation>
    <PMID>25217469</PMID>
  </reference>
  <reference>
    <citation>Hahn A, Kranz GS, Sladky R, Kaufmann U, Ganger S, Hummer A, Seiger R, Spies M, Vanicek T, Winkler D, Kasper S, Windischberger C, Swaab DF, Lanzenberger R. Testosterone affects language areas of the adult human brain. Hum Brain Mapp. 2016 May;37(5):1738-48. doi: 10.1002/hbm.23133. Epub 2016 Feb 15.</citation>
    <PMID>26876303</PMID>
  </reference>
  <reference>
    <citation>Smith LJ, Henderson JA, Abell CW, Bethea CL. Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology. 2004 Nov;29(11):2035-45.</citation>
    <PMID>15199371</PMID>
  </reference>
  <reference>
    <citation>Aggarwal M, Puri V, Puri S. Effects of estrogen on the serotonergic system and calcitonin gene-related peptide in trigeminal ganglia of rats. Ann Neurosci. 2012 Oct;19(4):151-7. doi: 10.5214/ans.0972.7531.190403.</citation>
    <PMID>25205989</PMID>
  </reference>
  <reference>
    <citation>Purves-Tyson TD, Handelsman DJ, Double KL, Owens SJ, Bustamante S, Weickert CS. Testosterone regulation of sex steroid-related mRNAs and dopamine-related mRNAs in adolescent male rat substantia nigra. BMC Neurosci. 2012 Aug 6;13:95. doi: 10.1186/1471-2202-13-95.</citation>
    <PMID>22867132</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Lanzenberger</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gender Dysphoria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Lynestrenol</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

